Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Purchased by Barclays PLC

Barclays PLC boosted its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 152.2% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 75,052 shares of the specialty pharmaceutical company’s stock after acquiring an additional 45,291 shares during the period. Barclays PLC’s holdings in Collegium Pharmaceutical were worth $2,899,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in COLL. Louisiana State Employees Retirement System grew its position in shares of Collegium Pharmaceutical by 1.9% during the 2nd quarter. Louisiana State Employees Retirement System now owns 16,500 shares of the specialty pharmaceutical company’s stock valued at $531,000 after acquiring an additional 300 shares during the period. Foundry Partners LLC grew its holdings in Collegium Pharmaceutical by 3.3% in the third quarter. Foundry Partners LLC now owns 15,781 shares of the specialty pharmaceutical company’s stock valued at $610,000 after purchasing an additional 509 shares during the period. CWM LLC increased its position in shares of Collegium Pharmaceutical by 97.5% in the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after buying an additional 736 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Collegium Pharmaceutical by 124.5% in the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 792 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Collegium Pharmaceutical by 10.9% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,745 shares of the specialty pharmaceutical company’s stock worth $314,000 after buying an additional 959 shares during the period.

Collegium Pharmaceutical Stock Performance

COLL opened at $29.06 on Wednesday. Collegium Pharmaceutical, Inc. has a twelve month low of $28.75 and a twelve month high of $42.29. The firm has a market capitalization of $937.19 million, a PE ratio of 12.53 and a beta of 0.80. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The firm’s 50-day moving average price is $32.30 and its 200 day moving average price is $34.30.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. HC Wainwright lifted their price target on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, September 5th. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $42.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.